CC-292 + rituximab

CC-292 + rituximab is an investigational combination therapy evaluated for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma. CC-292 (also known as AVL-292) is a potent, selective, covalent Bruton tyrosine kinase (BTK) inhibitor administered orally. Rituximab is an anti-CD20 monoclonal antibody targeting B lymphocytes. The combination is designed to synergistically inhibit B-cell receptor signaling and deplete malignant B cells. In phase 1 clinical studies, the doublet showed increased toxicity and insufficient efficacy improvement compared to other regimens. - CC-292 (AVL-292): small molecule, irreversible BTK inhibitor disrupting B-cell survival/proliferation - Rituximab: anti-CD20 chimeric monoclonal antibody mediating B-cell lysis via antibody-dependent cellular cytotoxicity and complement activation Developed for hematologic malignancies, particularly DLBCL and follicular lymphoma, the combination was investigated in a multicenter, phase Ib, dose-escalation trial (NCT02031419) but was not advanced due to safety/efficacy profile[1][2][3][4].

Other names

AVL-292 + rituximab